Researcher profile

Peter F. Thall

Peter F. Thall contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Applications Methodology

Trust snapshot

Quick read

Trust 15 - Baseline

3works

0followers

2topics

4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

preprint2020arXiv

A Bayesian Feature Allocation Model for Identification of Cell Subpopulations Using Cytometry Data

A Bayesian feature allocation model (FAM) is presented for identifying cell subpopulations based on multiple samples of cell surface or intracellular marker expression level data obtained by cytometry by time of flight (CyTOF). Cell subpopulations are characterized by differences in expression patterns of makers, and individual cells are clustered into the subpopulations based on the patterns of their observed expression levels. A finite Indian buffet process is used to model subpopulations as latent features, and a model-based method based on these latent feature subpopulations is used to construct cell clusters within each sample. Non-ignorable missing data due to technical artifacts in mass cytometry instruments are accounted for by defining a static missing data mechanism. In contrast to conventional cell clustering methods based on observed marker expression levels that are applied separately to different samples, the FAM based method can be applied simultaneously to multiple samples, and can identify important cell subpopulations likely to be missed by conventional clustering. The proposed FAM based method is applied to jointly analyze three datasets, generated by CyTOF, to study natural killer (NK) cells. Because the subpopulations identified by the FAM may define novel NK cell subsets, this statistical analysis may provide useful information about the biology of NK cells and their potential role in cancer immunotherapy which may lead, in turn, to development of improved cellular therapies. Simulation studies of the proposed method's behavior under two cases of known subpopulations also are presented, followed by analysis of the CyTOF NK cell surface marker data.

preprint2014arXiv

Bayesian Nonparametric Estimation for Dynamic Treatment Regimes with Sequential Transition Times

Dynamic treatment regimes in oncology and other disease areas often can be characterized by an alternating sequence of treatments or other actions and transition times between disease states. The sequence of transition states may vary substantially from patient to patient, depending on how the regime plays out, and in practice there often are many possible counterfactual outcome sequences. For evaluating the regimes, the mean final overall time may be expressed as a weighted average of the means of all possible sums of successive transitions times. A common example arises in cancer therapies where the transition times between various sequences of treatments, disease remission, disease progression, and death characterize overall survival time. For the general setting, we propose estimating mean overall outcome time by assuming a Bayesian nonparametric regression model for the logarithm of each transition time. A dependent Dirichlet process prior with Gaussian process base measure (DDP-GP) is assumed, and a joint posterior is obtained by Markov chain Monte Carlo (MCMC) sampling. We provide general guidelines for constructing a prior using empirical Bayes methods. We compare the proposed approach with inverse probability of treatment weighting. These comparisons are done by simulation studies of both single-stage and multi-stage regimes, with treatment assignment depending on baseline covariates. The method is applied to analyze a dataset arising from a clinical trial involving multi-stage chemotherapy regimes for acute leukemia. An R program for implementing the DDP-GP-based Bayesian nonparametric analysis is freely available at https://www.ma.utexas.edu/users/yxu/.

preprint2010arXiv

Bayesian Models and Decision Algorithms for Complex Early Phase Clinical Trials

An early phase clinical trial is the first step in evaluating the effects in humans of a potential new anti-disease agent or combination of agents. Usually called "phase I" or "phase I/II" trials, these experiments typically have the nominal scientific goal of determining an acceptable dose, most often based on adverse event probabilities. This arose from a tradition of phase I trials to evaluate cytotoxic agents for treating cancer, although some methods may be applied in other medical settings, such as treatment of stroke or immunological diseases. Most modern statistical designs for early phase trials include model-based, outcome-adaptive decision rules that choose doses for successive patient cohorts based on data from previous patients in the trial. Such designs have seen limited use in clinical practice, however, due to their complexity, the requirement of intensive, computer-based data monitoring, and the medical community's resistance to change. Still, many actual applications of model-based outcome-adaptive designs have been remarkably successful in terms of both patient benefit and scientific outcome. In this paper I will review several Bayesian early phase trial designs that were tailored to accommodate specific complexities of the treatment regime and patient outcomes in particular clinical settings.